[Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].Huijie Fan, Xingya Li, Jing Yuan et al.|PubMed|2019Cited by 5